- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging drugs for the treatment of Myelofibrosis
Authors
Keywords
-
Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 23, Issue 1, Pages 37-49
Publisher
Informa UK Limited
Online
2018-02-26
DOI
10.1080/14728214.2018.1445718
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor–Naïve Patients With Myelofibrosis
- (2017) Ruben A. Mesa et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
- (2017) John Mascarenhas et al. LEUKEMIA RESEARCH
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
- (2017) Ruben A Mesa et al. Lancet Haematology
- Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management
- (2016) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL
- (2016) N. Daver et al. BLOOD
- Does ruxolitinib prolong the survival of patients with myelofibrosis?
- (2016) Francisco Cervantes et al. BLOOD
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms
- (2016) A Hanif et al. BONE MARROW TRANSPLANTATION
- Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
- (2016) Srdan Verstovsek et al. Journal of Hematology & Oncology
- A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence
- (2016) A Tefferi et al. LEUKEMIA
- Outcome Improvement After Allogeneic Stem-Cell Transplantation in Myelofibrosis
- (2016) Nicolaus Kröger Journal of Oncology Practice
- Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results
- (2015) Francisco Cervantes et al. ANNALS OF HEMATOLOGY
- Early bone marrow involvement by mantle cell lymphoma
- (2015) P. W. Clement et al. BLOOD
- Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis
- (2015) N. Kroger et al. BLOOD
- A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
- (2015) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression
- (2015) Laura Pinton et al. Oncotarget
- MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
- (2014) D. Rondelli et al. BLOOD
- A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis
- (2014) C. L. Andersen et al. HAEMATOLOGICA
- CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
- (2014) A Tefferi et al. LEUKEMIA
- CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
- (2014) A Tefferi et al. LEUKEMIA
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Advances in myelofibrosis: a clinical case approach
- (2013) J. O. Mascarenhas et al. HAEMATOLOGICA
- U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype
- (2013) A Tefferi et al. LEUKEMIA
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- (2013) A Pardanani et al. LEUKEMIA
- Anti-transforming growth factor-β therapy in patients with myelofibrosis
- (2013) John Mascarenhas et al. LEUKEMIA & LYMPHOMA
- Epidemiology of myeloproliferative neoplasms in the United States
- (2013) Jyotsna Mehta et al. LEUKEMIA & LYMPHOMA
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis
- (2012) A. Deisseroth et al. CLINICAL CANCER RESEARCH
- Improving Survival Trends in Primary Myelofibrosis: An International Study
- (2012) Francisco Cervantes et al. JOURNAL OF CLINICAL ONCOLOGY
- Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
- (2012) Robyn M. Emanuel et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis
- (2012) Alfonso Quintás-Cardama et al. LEUKEMIA RESEARCH
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of thalidomide and lenalidomide as therapy for myelofibrosis
- (2011) E. Jabbour et al. BLOOD
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis
- (2010) J.S. Duffield et al. DRUG NEWS & PERSPECTIVES
- Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway
- (2010) Min Lu et al. EXPERIMENTAL HEMATOLOGY
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase-2 trial of low-dose pomalidomide in myelofibrosis
- (2010) K H Begna et al. LEUKEMIA
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
- (2010) A Tefferi LEUKEMIA
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
- (2009) N. Kroger et al. BLOOD
- Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells
- (2009) Y. Wang et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- PEG-IFN-α-2a therapy in patients with myelofibrosis
- (2009) Jean-Christophe Ianotto et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Recombinant interferon alpha (rIFNα-2b) may retard progression of early primary myelofibrosis
- (2009) R T Silver et al. LEUKEMIA
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
- (2008) A Quintás-Cardama et al. LEUKEMIA
- Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms
- (2008) L Bernard et al. LEUKEMIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now